tiprankstipranks
4basebio UK Societas (GB:4BB)
LSE:4BB

4basebio UK Societas (4BB) Share Price & Analysis

4 Followers

4BB Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range492.00p - 1,120.00p
Previous Close1,080p
Volume977.00
Average Volume (3M)2.81K
Market Cap
£137.66M
Enterprise Value133.71M
Total Cash (Recent Filing)£4.59M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)-22.9
Beta0.75
May 08, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares OutstandingN/A
10 Day Avg. Volume4,456
30 Day Avg. Volume2,805
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

14.66%0.00%0.00%85.34%
14.66% Insiders
0.00% Other Institutional Investors
85.34% Public Companies and
Individual Investors

4BB FAQ

What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 492.00p and its highest was 1120.00p in the past 12 months.
    What is 4basebio UK Societas’s market cap?
    Currently, no data Available
    When is 4basebio UK Societas’s upcoming earnings report date?
    4basebio UK Societas’s upcoming earnings report date is May 08, 2024 which is in 4 days.
      How were 4basebio UK Societas’s earnings last quarter?
      4basebio UK Societas released its earnings results on Sep 21, 2023. The company reported -0.289p earnings per share for the quarter, missing the consensus estimate of -0.28p by -0.009p.
        Is 4basebio UK Societas overvalued?
        According to Wall Street analysts 4basebio UK Societas’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does 4basebio UK Societas pay dividends?
          4basebio UK Societas does not currently pay dividends.
          What is 4basebio UK Societas’s EPS estimate?
          4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does 4basebio UK Societas have?
          4basebio UK Societas has 12,805,208 shares outstanding.
            What happened to 4basebio UK Societas’s price movement after its last earnings report?
            4basebio UK Societas reported an EPS of -0.289p in its last earnings report, missing expectations of -0.28p. Following the earnings report the stock price went down -5.738%.
              Which hedge fund is a major shareholder of 4basebio UK Societas?
              Currently, no hedge funds are holding shares in GB:4BB
              ---

              Company Description

              4basebio UK Societas

              4basebio UK Societas is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process to manufacture Good Manufacturing Practice grade DNA, suitable for use in gene therapies and DNA vaccines.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Eco Animal Health
              Futura Medical
              Genedrive
              Avacta Group plc
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis